Authors

Manmeet Ahluwalia, Miami Cancer InstituteFollow
Ahmad Ozair, Miami Cancer InstituteFollow
Atulya Khosla, Miami Cancer InstituteFollow
Shreyas Bellur, Miami Cancer InstituteFollow
Rupesh Kotecha, Miami Cancer InstituteFollow
Michael McDermott, Miami Neuroscience InstituteFollow
Minesh Mehta, Miami Cancer InstituteFollow
Ana Cristina Sandoval Leon, Miami Cancer InstituteFollow
Reshma Mahtani, Miami Cancer InstituteFollow

CTNI-08: Tucatinib, Trastuzumab, and Capecitabine with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR): A Multicenter Phase 1 Clinical Trial

Publication Date

11-15-2023

Presented At:

Annual Meeting. Society for Neuro-Oncology (SNO)

Content Type

Presentation

Publisher's Site:

View at Publisher Website

Additional Authors:

Additional authors and institutional affiliations

Citation

Ahluwalia, M., Ozair, A., Khosla, A., Bellur, S., Kotecha, R., McDermott, M., Mehta, M., Sandoval-Leon, A., Mahtani, R., & Peereboom, D. (2023). CTNI-08: Tucatinib, Trastuzumab, and Capecitabine with Stereotactic Radiosurgery in Patients with Brain Metastases from HER-2 Positive Breast Cancer (TUTOR): A Multicenter Phase 1 Clinical Trial. Neuro-Oncology, 25(Supplement_5), v74-v74. https://doi.org/10.1093/neuonc/noad179.0290